Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)

1990-472X

Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации

8000

10.18499/1990-472X-2022-0-90-40-49

Original Article

The influence of complex therapy on clinical and functional parameters and laboratory markers of patients with coexisting pathology of musculoskeletal system

Vasilyeva

L. V

-Starodubtseva

I. A

-Panina

I. G

-Zolotareva

M. A

Voronezh State Medical UniversityVoronezh City Hospital №3

15122022

904049

22012023

2022

Objective: to evaluate the efficacy of the use of diacerein in the complex therapy of secondary osteoarthritis in patients with rheumatoid arthritis. Materials and methods. 248 patients with secondary osteoarthritis (OA) in rheumatoid arthritis were enrolled in the trial (87,5% females and 12,5% males), with the mean age 47,04±9,72 years, activity on DAS 28 I and II . Patients were divided in 4 groups: group I (n=62) patients of secondary OA in RA on the basis of methotrexate (MT) took diacerein in complex with laser therapy (LT), patients of group II (n=60) - МТ +D, in group III (n=62) on the basis of МТ the course of LT and in group IV (n=64) - MT. Healthy were included in control group (n=40). The efficacy of treatment we estimated in 3 and 6 months with the use of indexes WOMAC, Lequesne, DAS 28, markers COMP and IL-1. Results and discussion. After 6 months of complex therapy, the advantage of using diacerein in relation to the dynamics of the functional indices WOMAC and Lequesne was noted. Against the background of taking MT (group IV), a decrease in inflammation markers was also noted. However, the dynamics of values is significantly less. A comparative analysis showed a statistically significant advantage (p<0.01) of the use of diacerein in combination with MT in relation to the dynamics of IL-1 and COMP in the blood serum of patients.

DAS 28secondary osteoarthritisrheumatoid arthritisDAS 28COMPdiacerein

вторичный остеоартрозревматоидный артритСOMPДиацереин

Aubert Carole E.ab, Fankhauser Niklausc, Vasques-Vidal Pedro-Manueld et al. Patterns of multimorbidity in internal medicine patients in Swiss university hospitals: a multicentre cohort study Swiss Med Wkly. 2019;149: 10.4414/smw.2019.20094

Гордеев А.В., Галушко Е.А., Савушкина Н.М., Демидова Н.В., Семашко А.С. Оценка мультиморбидного профиля (CIRS) при ревматоидном артрите. Первые результаты. Современная ревматология. 2019;13(3):10-16. doi.org/10.14412/1996-7012-2019-3-10-16

Louthrenoo, W., Nilganuwong, S., Nanagara, R. et al. Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial. Clin Rheumatol 38, 2461-2471 (2019). https://doi.org/10.1007/s10067-019-04587-1

Pavelka K, Bruyère O, Cooper C. et al. Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. Drugs Aging. 2017 May;34(5):413. doi: 10.1007/s40266-017-0457-7.

Arnett FC, Edworthy SM, Bloch DA et al. American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988; 31: 315-324. DOI: 10.1002/art.1780310302

Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases 2010; 69: 1580-1588. DOI:10.1136/ard.2010.138461

Restrictions of the use of diacerein -containing medicines. Restrictions intended to limit risks of severe diarrhoea and effects on the liver. 4 September 2014 EMA / 544268/2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diacerein/European_Commission_final_decision/WC500173144.pdf (дата обращения 19.11.2022).

Josef S Smolen, Robert B M Landewé , Johannes W J Bijlsma et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655.

Буйлин ВА Магнитолазерная терапия заболеваний суставов и позвоночника. Москва: Адвансед Солюшнз; 2011.[Builin VA Magnitolazernaya terapiya zabolevanii sustavov i pozvonochnika. Moskva: Advansed Solyushnz; 2011.(In Russ.)]

10.

Москвин СВ Эффективность лазерной терапии. Москва; Тверь: Триада; 2014. [Moskvin S.V. Effektivnost' lazernoi terapii. Moskva; Tver': Triada; 2014. (In Russ.)]

11.

Москвин СВ, Буйлин ВА Основы лазерной терапии. Тверь: Триада; 2006.[Moskvin S.V., Builin VA Osnovy lazernoi terapii. Tver': Triada; 2006 (In Russ.)]

12.

Xing Suna, Ru Li a, Yueming Cai et al. Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region The Lancet Regional Health - Western Pacific 15 (2021) 100240

13.

Daien C, Hua C, Gaujoux-Viala C et al. Update of French society for rheumatology recommendations for managing rheumatoid arthritis. Joint. Bone. Spine. 2019. 86(2), 135-150

14.

Brosseau L, Welch V, Wells G. et al. Low level laser therapy for osteoarthritis and rheumatoid arthritis: a metaanalysis. Rheumatology 2000; 27: 1961-1969.